Test Price
2,800 AED✅ Home Collection Available
NANOS1 Gene Oligoasthenoteratozoospermia (OAT) Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Confidential Clinical Synopsis
Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO-accredited NGS processing with orthogonal variant confirmation.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic post-test genetic counselling and result interpretation provided by a board-certified Consultant Medical Geneticist.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The NANOS1 gene test identifies pathogenic variants linked to spermatogenic failure, enabling a definitive molecular diagnosis of oligoasthenoteratozoospermia (OAT). This targeted next-generation sequencing assay interrogates all coding exons and flanking splice-site regions of the NANOS1 locus, providing conclusive genetic evidence for severe male infertility. Results guide personalised reproductive strategies, including pre-implantation genetic testing and assisted reproductive technology planning.
| Feature | Our Test (DNA Labs UAE) | Closest Alternative |
|---|---|---|
| Precision | Full NGS coverage of NANOS1 exons, intron-exon boundaries, and splice sites at > 100x depth | Limited panel or single-gene Sanger sequencing (lower resolution, may miss mosaic variants) |
| Method | Illumina NovaSeq 6000 paired-end chemistry with LC-MS/MS orthogonal variant validation | Conventional PCR followed by Sanger capillary electrophoresis without orthogonal confirmation |
| Turnaround | 21 calendar days (3-week expedited workflow with weekly status updates) | 4–6 weeks routine, often without interim progress communication |
Physician Insight & Safety Protocols
Consultant Medical Genetics Commentary
“The NANOS1 gene plays a critical role in germ cell maintenance and spermatogonial stem cell renewal. A pathogenic variant in this gene disrupts the sperm production cascade, leading to oligoasthenoteratozoospermia. However, this molecular finding must always be interpreted alongside a comprehensive semen analysis, reproductive hormone profile, and detailed family history. The genetic result provides the ‘why’ — the clinical picture guides the ‘what next’. Genetic counselling before and after testing is essential for informed reproductive decision-making.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Safety Notice
Critical Clinical Precautions
- Do not discontinue, adjust, or initiate any fertility treatment or medication based solely on genetic test results without a formal consultation with your treating physician or reproductive endocrinologist.
- A confirmed NANOS1 mutation does not automatically preclude natural conception; always correlate with semen parameters and clinical evaluation before therapeutic decisions.
- All test results must be reviewed in a post-test genetic counselling session to ensure accurate understanding of inheritance patterns and recurrence risks.
Safety Exclusion Criteria & Emergency Red Flags
Contraindications for Testing
- Inability to provide valid informed consent — including minors who cannot independently consent under UAE Federal Law No. 2 of 2019.
- Severe active psychiatric illness with suicidal ideation — immediate psychiatric evaluation is mandatory prior to any genetic testing.
- Known coagulopathy or current anticoagulant therapy without written medical clearance from a haematologist or primary physician (applies to venipuncture collection).
- Emergency Red Flags: acute psychological crisis, self-harm ideation, or escalating family conflict following result receipt — contact emergency services or proceed to the nearest hospital accident & emergency department immediately.
Patient FAQ & Clinical Guidance
1. What exactly does the NANOS1 gene test diagnose?
The test detects inherited pathogenic mutations in the NANOS1 gene that directly cause oligoasthenoteratozoospermia (OAT) — a severe male infertility disorder characterised by simultaneously low sperm count, poor progressive motility, and abnormal sperm morphology. Identifying the genetic root enables accurate prognosis, targeted reproductive counselling, and informed decisions regarding assisted reproductive technologies such as intracytoplasmic sperm injection (ICSI) with or without pre-implantation genetic testing.
2. How is the sample collected, and is it painful?
A standard peripheral blood draw (two EDTA tubes, 4–6 mL total) is performed by a certified phlebotomist during a VIP home visit. The procedure is minimally invasive, typically described as a brief pinch sensation lasting seconds. Alternatively, a single finger-prick dried blood spot on an FTA card may be used for individuals with difficult venous access. All collections follow strict cold-chain protocols to preserve nucleic acid integrity.
3. Can this test be used for pre-implantation genetic testing (PGT-M) or family planning?
Yes. A confirmed pathogenic NANOS1 mutation enables reproductive partners to pursue pre-implantation genetic testing for monogenic disorders (PGT-M). This allows selection of embryos free of the familial variant, preventing transmission of OAT to offspring. A mandatory pre-test genetic counselling session is recommended to discuss inheritance patterns, recurrence risks, and the technical success rates of PGT-M before commencing any assisted reproduction cycle.
4. What is the turnaround time, and how will I receive results?
The standard turnaround time is 21 calendar days from sample receipt at the laboratory. Results are delivered through a secure, encrypted digital portal with a downloadable PDF report. A telephonic post-test counselling session with a consultant medical geneticist is scheduled within 48 hours of report issuance to explain findings, answer questions, and coordinate with your treating physician.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
All genetic testing and data handling procedures strictly conform to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient genomic data is encrypted at rest and in transit, access-logged, and retained only for the clinically mandated duration before secure erasure.
Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring every test is accompanied by documented informed consent and a clear clinical indication from a licensed physician.
DNA Labs UAE is a DHA-licensed facility (License No. 1143) operating exclusively within Dubai Healthcare City, subject to regular audit by the Dubai Health Authority and the UAE Ministry of Health & Prevention.
Clinical & Logistical Metadata
| Test Name | NANOS1 Gene Sequencing – Oligoasthenoteratozoospermia (OAT) Molecular Diagnostics |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21 calendar days (3-week expedited workflow from sample receipt) |
| Sample Type / Matrix | Peripheral whole blood (EDTA, 4–6 mL) or dried blood spot on FTA card |
| Methodology Used | Targeted next-generation sequencing (Illumina NovaSeq 6000) with LC-MS/MS orthogonal validation |
| ICD-10-CM Code | N46.11 |
| LOINC Code | 21636-6 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians